Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.37 |
| ▸ | PIK3CA known ✓ | P42336 | 3/20 | 0.35 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274733 | 0.98 | KMT2A (0.49) | KMT2APKMLMNAMAPTNPC1 | |
| SCHEMBL2154504 | 0.78 | KMT2A (0.47) | KMT2APKMLMNAMAPTNPC1 | |
| SCHEMBL14966577 | 0.77 | KMT2A (0.47) | KMT2ALMNANPC1HTTRAB9A | |
| Hydrochloric Acid SCHEMBL7597445 | 0.77 | LMNA (0.43) | KMT2ALMNAMAPTHTTALDH1A1 | |
| SCHEMBL7022152 | 0.76 | KMT2A (0.49) | KMT2APKMLMNAMAPTNPC1 | |
| SCHEMBL30739194 | 0.76 | IDO1 (0.50) | KMT2APKMLMNAMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL20270668 | 0.75 | TDP1 (0.48) | KMT2AMAPTALDH1A1TDP1CYP3A4 | |
| SCHEMBL6575977 | 0.74 | KMT2A (0.47) | KMT2APKMLMNAMAPTNPC1 | |
| SCHEMBL16504100 | 0.74 | MEN1 (0.35) | KMT2ALMNANPC1HTTRAB9A | |
| SCHEMBL15607186 | 0.72 | KMT2A (0.54) | KMT2APKMLMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741944-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-8546441-B2 | PDK-1/AKT signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541460-B2 | Phosphoinositide-dependent kinase-1 (PDK-1) inhibitors; for the treatment and prevention of cancer in humans; 4-[5-(2-Phenanthracenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenecarboxamide | THE OHIO STATE UNIVERSITY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8445483-B1 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | disclosed |
| EP-1696907-B1 | PDK-1/AKT SIGNALING INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8080574-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-8039502-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-01-20 | — | — | US | disclosed |
| US-5451588-A | Treatment of migraines | MERCK SHARP & DOHME LTD. (GB) | 1995-09-19 | — | — | US | disclosed |
| EP-0603432-A1 | Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated | SMITHKLINE BEECHAM PLC (GB) | 1994-06-29 | — | — | EP | disclosed |
| EP-0591280-A1 | USE OF TETRAHYDROCARBAZOLE DERIVATIVES AS 5HT1-RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-13 | — | — | EP | disclosed |
| US-5298520-A | Triazole containing indole derivatives | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-29 | — | — | US | disclosed |
| WO-1993000086-A1 | USE OF TETRAHYDROCARBAZONE DERIVATIVES AS 5HT1 RECEPTOR AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-01-07 | — | — | WO | disclosed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | disclosed |
| US-4855314-A | VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED | GLAXO GROUP LIMITED (GB) | 1989-08-08 | — | — | US | disclosed |
| CN-1030409-A | Indole derivatives and preparation method thereof | GLAXO GROUP LTD (GB) | 1989-01-18 | — | — | CN | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | PTGS2 2366/4885PIK3CA 184/4885PIK3CD 153/4885 |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PTGS2 3793/4885PIK3CA 515/4885PIK3CD 316/4885 |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PTGS2 3793/4885PIK3CA 515/4885PIK3CD 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.